Introduction {#sec1-1}
============

The unavoidable anatomical distortion of bowel anatomy due to surgical resections for colorectal cancer (CRC) may lead to intestinal functional disturbances \[[@ref1]\]. Preoperative preparation strategies, such as mechanical bowel preparation may disturb the well-established functional balances between enteric flora and normal large bowel function \[[@ref2]\]. Bowel disorders may directly or indirectly affect health-related quality of life (HRQoL) and this may be reflected to proportional alterations in the scoring of standardized measurement tools, such as HRQoL questionnaires \[[@ref3]-[@ref7]\]. A validated instrument that assesses gastrointestinal function is the Gastro-Intestinal Quality Life Index (GIQLI) \[[@ref3]-[@ref5]\]. GIQLI may offer valuable insight in rating postoperative gastrointestinal function status at CRC patients. The 30-item questionnaire (QLQ-C30) of the European Organization for Research and Treatment of Cancer (EORTC) has already widely assessed CRC patients' HRQoL and it includes items on gastrointestinal function, such as the symptom domains "diarrhea" and "constipation" \[[@ref4],[@ref6],[@ref7]\]. HRQoL instruments may offer "functional surveillance" by monitoring, ranking and quantifying the "subjective" patient's symptoms.

Initial HRQoL postoperative deterioration and postcolectomy gastrointestinal disturbances are expected to be temporary enduring 3-6 months \[[@ref7]\]. Interventional strategies and enhancing therapeutic regimens at the immediate postoperative period may have a soothing effect on patients' symptoms. Probiotics are cultures of live microorganisms that might beneficially affect the host by improving the composition and the equilibrium of indigenous microflora \[[@ref8]\]. Prebiotics are nondigestible ingredients (fibers) that reach the colon and serve as substrate for fermentation by probiotics and indigenous colonic bacteria to nutrients beneficially improving host health \[[@ref9]\]. Synbiotics are the combination of probiotics and prebiotics and are believed to be more efficient in terms of gut health and function \[[@ref10]\]. Administration of pro- and/or synbiotics may serve as one of the supportive modulating dietary supplement-based strategies in CRC patients \[[@ref11]-[@ref25]\].

Studies reporting on the effects of pro-/synbiotics on functional outcome, gastrointestinal symptoms and HRQoL after CRC surgery are rather scarce \[[@ref14],[@ref22],[@ref25]\]. In an effort to clarify the effects of early postoperative administration of synbiotics on bowel functional outcome, as this is measured by gastrointestinal-oriented HRQoL instruments and domains, we prospectively carried out a randomized trial in a selected cohort of patients undergoing colorectal resection for cancer. This study aimed to justify the early postoperative use of oral synbiotics for the minimization of the adverse effect of surgery on the short- and mid-term gastrointestinal symptoms-associated HRQoL.

Patients and methods {#sec1-2}
====================

Study design {#sec2-1}
------------

This was a prospective, double-blind, randomized controltrial (RCT) of two groups. The study was carried out in the First Department of Propaedeutic Surgery of Athens Medical School at Hippocration Hospital, Athens, Greece.

Participants {#sec2-2}
------------

Patients eligible for inclusion were those with histological documentation of cancer of the colon or rectum, operated between July 2008 and April 2012. Patients of both genders, aged between 18 and 80 years, who were candidates for elective colorectal resection for cancer were included in the study. Patients were excluded if they: denied written informed consent; were pregnant; had hereditary cancer; had a history of inflammatory bowel disease; had metastatic disease at presentation; required permanent or temporary stoma; had emergency operation; had major postoperative complications; had disease progression during the study period; or did not tolerate liquid diet by the 5^th^ postoperative day (POD).

Study intervention {#sec2-3}
------------------

### Randomization and method of allocation concealment {#sec3-1}

The study patients were randomized before surgery to receive either synbiotics (Synbiotics group) or placebo (Control group). Equal randomization was accomplished using a computer-generated random allocation schedule. The method of allocation concealment was sequentially numbered sealed opaque envelopes technique. Both synbiotics and placebo preparations were in foil-sealed sachets stored in identical numbered containers. Both study products were white powders, identical in weight, smell, and taste. Thus, the identity of the specific product was blind to participants, support staff and investigators for the entire duration of the study period.

During the study period, of the 75 patients who initially consented to participate, 38 in the Synbiotics group and 37 patients in the Control group completed the entire trial ([Fig. 1](#F1){ref-type="fig"}).

![Flow chart of 75 patients with colorectal cancer undergone surgical treatment and randomly assigned either to receive synbiotics (Synbiotics group) or placebo (Control group)\
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### Arms assigned interventions and study medications {#sec3-2}

A specific multistrain/multifiber synbiotic composition of prebiotics and probiotics (Synbiotic Forte™, "IONIA" Pharmaceuticals, Athens, Greece) was administered at the active comparator arm of the study. It contained 10 \[[@ref11]\] of each of four lactic acid bacteria (LAB): *Pediococcus pentosaceus* 5-33:3, *Leuconostoc mesenteroides* 32-77:1, *Lactobacillus paracasei ssp. paracasei* 19, and *Lactobacillus plantarum* 2362, and 2.5 g of each of the four fermentable fibers (prebiotics): b-glucan, inulin, pectin and resistant starch. The synbiotics were delivered in sachets and then mixed with water (12 g in 250 mL of water once daily). The treatment started on the day patients tolerated *per os* liquid intake (2^nd^-4^th^ POD). The intervention period lasted 15 days. The patients belonging to the placebo comparator arm received only the 4 fibers and no LAB (12 g in 250 mL of water once daily for 15 days). All the subjects were interviewed by a dedicated research fellow (KP) and reactions to the product, and any adverse events occurring in the 15-day period were recorded. During the study period, no parenteral or enteral nutritional supplementation was given. All patients received a regular diet preoperatively, and a low-residue diet 1 day before surgery. For mechanical bowel preparation the afternoon before the operation all patients were given 45 mL of regimen containing monobasic sodium phosphate monohydrate and dibasic sodium phosphate heptahydrate and the dose was repeated 4-6 h later. For chemoprophylaxis, 500 mg of metronidazole and 1 g of cefoxitin were given prior to anesthesia and continued for 24 h after the operation. During the postoperative period, all patients received the regular parenteral hydration infusion.

Outcome measures and questionnaires {#sec2-4}
-----------------------------------

The primary end point of the study was the assessment of gastrointestinal function-related quality of life at 1, 3 and 6 months postoperatively by the use of the validated questionnaire GIQLI. Secondary endpoint was the assessment of functional bowel disorders ("diarrhea", "constipation") at 1, 3 and 6 months postoperatively based on the respective domains of the validated instrument EORTC QLQ-C30.

Patients visited a clinic dedicated to the post-colectomy "functional and oncologic surveillance" and were asked to answer the HRQoL questionnaires at fixed postoperative assessment time-points: 1, 3 and 6 months. Completeness of answers to the questionnaires was regularly checked. Only few patients required a family member's assistance due to low educational background and vision problems. Baseline HRQoL scores had already been taken at patients; admission, prior to any treatment.

The GIQLI questionnaire consists of 36 questions referring to a specific symptom, answered by the patient using five-point Likert scales \[[@ref3]-[@ref5]\]. Scoring of individual questions is summarized in five categories (emotional function, physical function, social function, symptoms, and treatment reaction). "Global" GIQLI score is calculated by summarizing the points from all 36 questions and its highest score is 144 points. An elevated GIQLI score means a higher quality of life.

The EORTC QLQ-C30 consists of 30 questions \[[@ref4],[@ref6],[@ref7]\]. All data undergo linear transformation and the scales for severity of symptoms range from 0 (least) to 100 (worst). The symptom scales "constipation" (item No 16) and "diarrhea" (item No 17) were used in the current study.

Ethical considerations {#sec2-5}
----------------------

The study was approved by the ethics committee of Hippocration Hospital, Athens, Greece. The purpose of the study was explained clearly to the patients and their informed written consent was obtained. The trial was registered at ClinicalTrial.gov of the National Institute of Health with the identifier number NCT01479907 and assigned name "SYΝBIOTICSCOLON".

Statistical analysis {#sec2-6}
--------------------

Continuous data was presented as mean ± standard error of the mean (SEM) and categorical data as percent (%). SPSS statistical software, version 18 (SPSS, Inc., Chicago, IL) was used for all analyses. For numerical data the *t*-test while for categorical data the chi-square test with the Fisher exact test when appropriate were used. Modelling was performed with linear mixed models which are a variant of generalized linear models permitting flexibility of modeling not only the means of the data but their variances and covariances as well. The longitudinal nature of the data was also adjusted. Estimators were adjusted for confounding variables as described in each test. For numerical data that did not follow the normal distribution non-parametric tests were used (Mann-Whitney, Kosmolgorov-Smirnov). Tests were considered statistically significant if P\<0.05. The goal for the study was set as a change in the "Global score" of the GIQLI questionnaire between the two groups of at least 10%. The calculated sample size was 33 patients per arm giving 80% power. Statistically significant differences were also evaluated for their magnitude using Cohen's d classification. If Cohen's d is \<0.2 the difference is considered of small, 0.2\<d\<0.5 of medium and when d\>0.8 of high clinical significance.

Results {#sec1-3}
=======

No statistically significant differences were observed between the two groups regarding age, gender, site of tumor, type of surgery or stage ([Table 1](#T1){ref-type="table"}), comorbidities and medications. In general, no bowel motility affecting medications were used by any of patients post-operatively and there was no significant difference between the two groups regarding the use of narcotics after their discharge to home. The same standard peri-operative antibiotic chemoprophylaxis appropriate for colorectal resection (2^nd^ generation cephalosporin and metronidazole first dose pre-operatively and additional doses until the end of the first POD) was delivered to both groups. Inpatient diet was controlled and did not differ between the groups. The percentages of patients subjected to adjuvant treatment were not different between the groups and none of the patients had pre-operative radiotherapy. When the 12 right colectomy specimens of the Synbiotics group patients were compared with the 11 Control group right colectomies, no significant differences were observed in terms of the resected terminal ileum length (mean±SEM: 8.5±1.1 vs. 8.2±1.3 cm, P= 0.43) and the amount of large bowel removed (34.8±4.6 vs. 35.7±4.1 cm, P= 0.34). Likewise, no bowel length differences were revealed between the 14 Synbiotics and the 17 Control group sigmoidectomies (24.8±2.6 vs. 27.1±3.1 cm, P=0.18). All low anterior resections for the rectal cancer of the study were restored in a stapled end-to-end fashion at a height of 7.2±1.8 and 6.9±2.1 cm from anal verge at the Synbiotics and Control groups, respectively (P=0.22). No statistically significant difference was observed between the two groups regarding the baseline GIQLI scores and EORTC QLQ-C30 "diarrhea" and "constipation" domains' scores preoperatively ([Table 2](#T2){ref-type="table"}).

###### 

Demographic data of patients receiving synbiotics or placebo

![](AnnGastroenterol-29-56-g002)

###### 

Baseline scores for GIGLI and EORTC QLQ-C30 "diarrhea" and "constipation" domain

![](AnnGastroenterol-29-56-g003)

GIQLI {#sec2-7}
-----

Measured GIQLI "Global scores" at the postoperative assessment time-points were better at the Synbiotics than in the Control group \[77±1.67 vs. 71.36±1.69, P=0.01 (1 month), 77±1.7 vs. 72.5±1.73, P=0.03 (3 months), 79.23±1.82 vs. 72.75±1.85, P=0.01 (6 months)\]. Changes in GIQLI scores through time were examined using linear mixed models with dependent variable the scores over time and covariates the group, age, gender, stage, location, chemotherapy, and procedure. Multivariate linear mixed model analysis showed that synbiotics administration was the only independent statistically significant factor for a substantial amelioration of GIQLI "Global score" (b 5.42, SE (b)1.8, 95% CI 1.78-9.1, P=0.004, [Fig. 2A](#F2){ref-type="fig"}). The assessment time-point was not a significant factor for GIQLI score in the model except for the 6 month- score, which was significantly better than the preoperative one (b 3.69, SE (b)1.58, 95% CI:6.58-0.58, P=0.02). The effect size of the difference expressing the magnitude of this association, measured by Cohen's d, was 0.69 and that was considered as medium to high. Interaction between group and time was also tested in the group but was not found statistically significant.

![(A) Global score of GIQLI questionnaire (B) and symptoms domain, (C) emotional, (D) and social function domain; score between groups at 1, 3 and 6 months post operatively. Substantial change over time was noted between groups in favor of Synbiotics group\
SE, standard error](AnnGastroenterol-29-56-g004){#F2}

No statistically significant change occurred between the two groups regarding GIQLI "symptoms" domain over time. The change in each group is shown in [Fig. 2B](#F2){ref-type="fig"}. Linear mixed modeling for the emotional subdomain showed a substantial amelioration during followup in Synbiotics group patients (b1.83, SE(b)0.68, 95% CI0.48-3.2, P=0.009, [Fig. 2C](#F2){ref-type="fig"}). Emotional subdomain scores amongst assessment time-points did not differ significantly. Females had significantly lower physical function subdomain scores compared to males (b-1.75, SE(b)0.69, 95% CI-3.14\--0.37, P=0.013). Finally, the social domain showed a substantial increase in Synbiotics group patients (mean steady contrast between the two groups: 0.72±0.30, P=0.03, [Fig. 2D](#F2){ref-type="fig"}).

EORTC QLQ-C30 {#sec2-8}
-------------

Domains referring to "diarrhea" and "constipation" were isolated. The greater the score of the EORTC QLQ-C30 symptoms domains was, the worse the outcome. The "diarrhea" score was analyzed by subtracting the score at each time point from the baseline. Each difference was then compared between the two groups. The equation was ScC30ti- ScC30t0. The lower the difference was the better the outcome. As shown at [Fig. 3](#F3){ref-type="fig"}, the mean difference in the Synbiotics group remained negative at all time-points. Therefore, at all time-points the score was always lower than that at baseline, highlighting a postoperative improvement. The values reached statistical significance between the two groups when compared at 3 months and 6 months assessment time-points (-13.33±5.45 vs. 4.04±5.6, P=0.04 and -19.1±6.3 vs. 2.01±5.45, P=0.003, respectively). The same analysis was used for the "constipation" domain. However, no statistically significant change was observed (data not shown).

![Differences between the two groups regarding "diarrhea" domain of EORTC-C30. The equation was ScC30ti- ScC30t0. Horizontal line represents zero. The lower the difference the better the outcome\
\*denotes P\<0.05, EORTC-QLQ, 30-item questionnaire of the European Organization for Research and Treatment of Cancer](AnnGastroenterol-29-56-g005){#F3}

Discussion {#sec1-4}
==========

In the current randomized study early postoperative synbiotics administration appeared to have a beneficial effect on postcolectomy gastrointestinal function, as that was indicated by the better GIQLI scores at all postoperative assessment time-points, as well as the significant amelioration of the symptom "diarrhea", as assessed by the respective EORTC QLQ-C30 domain. The beneficial action of probiotics supplementation in gastrointestinal disorders has been recognized. Restoration of gut balance, inhibition of the epithelial and mucosal adherence of pathogens, introduction of lower colonic pH favoring the growth of nonpathogenic species, and stimulation of immunity during or after antibiotic treatment through receptor competition may be related to the positive gastrointestinal traits and properties of pro-/synbiotics \[[@ref26]\]. In keeping with our results, the use of pro-/synbiotics to postoperative CRC patients has been reported to be beneficial in alleviating gastrointestinal symptoms, including diarrhea, the first defecation time, abdominal pain and flatulence \[[@ref14],[@ref24],[@ref25]\]. Probiotics have been associated with a reduction and prevention of non-colectomy-related diarrheas \[[@ref27],[@ref28]\].

In general, early postoperative oral nutrition is regarded as an essential part of fast track recovery after colorectal surgery. Food intake can stimulate gastrointestinal peristalsis in the early postoperative period, attenuates catabolism and potentially decreases infectious complications. Synbiotics may play an additional beneficial role on the context of fast track and enhanced recovery programs after colorectal surgery but definite suggestions are not currently plausible since no fast track protocols integrating the administration of synbiotics have been tried yet in the clinical practice.

The strength of our study lies at the repetitive assessment of patients at fixed assessment time-points and the use of validated questionnaires to objectify the patients' subjective symptomatology. Only one other group of investigators has utilized a general, non-specific HRQoL questionnaire in assessing probiotics effects at colectomized patients \[[@ref22]\]. Improvements in the functional outcome and/or HRQoL were observed in all groups after administration of probiotics, with the right colectomy and proctectomy groups mostly benefited \[[@ref22]\].

Different types of colorectal resections were included in our study and this constitutes a potential limitation on deriving definitive conclusions on the accurate beneficial role of synbiotics on specific subsets of patients. Another limitation of our study is its complete clinical orientation in regards to outcome measures and the lack of any theoretical explanation that could be provided by associated laboratory or microbial assays. Albeit, it would be more compelling if supporting data regarding actual changes in the bowel microbiota had been included. It has been, though, sufficiently demonstrated that the use of probiotics after surgery has markedly improved intestinal microbial populations \[[@ref14]-[@ref16]\]. Although local immune function restoration by synbiotics is easily conceivable, improvement infunctional state may not be fully explainable. An explanation could involve immune-mediated neural local and systemic mechanisms \[[@ref29]\]. Dendritic cells in the gastrointestinal tract are able to interact with commensal bacteria and the nerves embedded in the gut wall \[[@ref29]\]. The vagus nerve has an important role in signaling from the gut to the brain and can be stimulated by bacterial products or inflammatory cytokines \[[@ref30]\]. Synbiotics-induced modulation of vagal responses indirectly affecting the brain function itself may be speculated. Indeed, in our study, non-gastrointestinal GIQLI domains, such as emotional and social function were improved after synbiotics supplementation. Administration of a probiotic formulation has significantly attenuated psychological distress in human volunteers and reduced anxiety-induced behavior in a rat model \[[@ref31]\].

###### Summary Box

**What is already known:**

Synbiotics are used as a supportive dietary supplement-based strategy in patients after colectomies for cancerSynbiotics administration has been shown to alleviate gastrointestinal symptoms such as diarrhea, abdominal pain and flatulence in patients after colectomies for colorectal cancerImprovement in the functional outcome of colectomized patients has been shown only by one group using a non-specific HRQoL questionnaire

**What the new findings are:**

Early postoperative synbiotics administration improved post-colectomy gastrointestinal function based on better GIQLI scores at all postoperative assessment time-pointsThe early administration of synbiotics in patients after colectomy for colorectal cancer led to significant amelioration of "diarrhea" based on the EORTC QLQ-C30 questionnaire

Probiotics may alleviate irritable bowel syndrome (IBS) symptoms \[[@ref32]\]. Bowel resections may induce an IBS-like transient gut dysfunction, both due to sensitive and motor disruptions of the visceral nerves, as well as changes in the bacterial ecosystem of the intestine. Implicating pathophysiological mechanisms may be similar. It has been suggested that the generation of nitric oxide (NO), a gas with immuno-modulating but also neuron-modulating properties, by lactobacilli could play an important role \[[@ref33]\]. Synbiotics positive effects on neuro-motor/sensitive locoregional transmission may be more complex and needs further evaluation. The sustained positive effects of synbiotics over time in our study may be related to the early "conditioning" of bowel to a better state of function via its repopulation by the "non-pathogenic" microbiota and the restoration of a "better" mucosa. Nevertheless, these tempting speculations need further confirmation by additional studies.

Despite the tantalizing multitude of trials on the potentially positive role of pre-/pro-/synbiotics, a straightforward translation into a clinical evidence-based strategy remains still unlikely. Incorporation of pre-/pro-/synbiotics formulations in the perioperative management of the CRC patient could be fully supported if further evidence from RCTs with all clinical relevant end-points will be accumulated in the future.
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